Xenon Pharmaceuticals Inc. (XENE)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Xenon Pharmaceuticals Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Xenon Pharmaceuticals Inc. (XENE) has returned 29.74% so far this year and 73.32% over the past 12 months. Looking at the last ten years, XENE has achieved an annualized return of 23.83%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.

Based on dividend-adjusted daily data since Nov 5, 2014, XENE's average daily return is +0.14%, while the average monthly return is +2.63%. At this rate, your investment would double in approximately 2.2 years.

Historically, 50% of months were positive and 50% were negative. The best month was Oct 2021 with a return of +103.9%, while the worst month was Mar 2017 at -50.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.

On a daily basis, XENE closed higher 48% of trading days. The best single day was Oct 4, 2021 with a return of +101.9%, while the worst single day was Mar 24, 2017 at -52.8%.

Xenon Pharmaceuticals Inc. has an annualized alpha of 29.55%, beta of 0.85, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since November 06, 2014.

• This stock captured 124.10% of S&P 500 Index gains and 100.95% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

XENE ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Xenon Pharmaceuticals Inc. (XENE) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Xenon Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Xenon Pharmaceuticals Inc. was 90.43%, occurring on Nov 14, 2017. Recovery took 977 trading sessions.

The current Xenon Pharmaceuticals Inc. drawdown is 7.35%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Xenon Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Xenon Pharmaceuticals Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.